Summit musculoskeletal, infectious news

Summit said it will focus on the clinical development of programs for Duchenne muscular dystrophy (DMD) and Clostridium difficile infections. The company said the change in strategy will "curtail internal discovery-stage research," which is conducted by about half of the company, and said it is consulting with staff affected by the change.

Summit also said it will progress its program of preclinical O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors through to an undisclosed technical milestone, after which the company said it will evaluate its options for moving the program forward. The inhibitors were developed using Summit's Seglin technology. ...